hepatocellular carcinoma
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
hepatocellular carcinoma
Jul 9, 2024, 10:44 |
Insight
GLP-1s lowers risk of 10 obesity-associated cancers
Ron DePinho, Professor and Past President of MD Anderson Cancer Center, shared a post on…
Jul 8, 2024, 18:50 |
Blog
Tumor Board Tuesday on Durva + TACE for HCC
Tumor Board Tuesday published the following post on X: “Did you know that there are…
Jul 5, 2024, 02:30 |
Drugs
Ipilimumab and Nivolumab for patients with unresected advanced Hepatocellular Carcinoma - ESMO
ESMO shared on LinkedIn: "Benefits reported for the combination of ipilimumab and nivolumab further expand…
Jul 5, 2024, 02:27 |
Blog
ESMO - Ipilimumab and nivolumab in unresected advanced Hepatocellular Carcinoma
ESMO shared on X: "Benefits reported for the combination of ipilimumab and nivolumab further expand alternative…
Jun 27, 2024, 02:53 |
Blog
Tanja Obradovic: Tempest Therapeutics just announced very good results from ongoing global clinical study with Amezalpat
Tanja Obradovic shared on LinkedIn: . “Are we to expect completely new mechanism of action…
Jun 23, 2024, 14:23 |
Blog
Continuous Risk Score Predicts Waitlist and Post-Transplant Outcomes in HCC
Arndt Vogel shared on X: "Continuous Risk Score Predicts Waitlist and Post-Transplant Outcomes in HCC Despite…
Jun 16, 2024, 20:00 |
Insight
Daneng Li: SKYSCRAPER-14 a Phase III study on advanced hepatocellular carcinoma
Daneng Li, GI Medical Oncologist at City of Hope, shared on X/Twitter: "Out now, the…
May 26, 2024, 16:38 |
Blog
Zouina Sarfraz: Two of my abstracts have been published for the 2024 ASCO Annual Meeting
Zouina Sarfraz, Associate Editor at BMC, shared a post on LinkedIn: "I am pleased to announce…
May 24, 2024, 13:24 |
Insight
Erman Akkus Summarizes 5-year Results of CheckMate 040
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: “Nivolumab plus ipilimumab…
May 23, 2024, 11:18 |
Blog
Sarabjot Pabla: Our latest molecular tumor board with a case of recurrent HCC
Sarabjot Pabla, Head of Clinical and Research Bioinformatics at OmniSeq, shared a post on LinkedIn:…
May 17, 2024, 16:56 |
Insight
Piotr Wysocki: Liver resection vs nonsurgical treatments in patients with early multinodular hepatocellular cancer
Piotr Wysocki recently posted on LinkedIn: "Current Barcelona Clinic Liver Cancer guidelines do not support…
May 15, 2024, 14:07 |
Blog
Rasha Aboelhassan: I'm honoured to be a part of the HCC committee in Nasser Institute
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn: “Management of…
May 5, 2024, 13:13 |
Blog
Dr. Tim Greten receives 2024 Innovation Grant from the Cholangiocarcinoma Foundation! - NCI Center for Cancer Research
NCI Center for Cancer Research shared on LinkedIn: "STAFF SPOTLIGHT: Congratulations to Dr. Tim Greten, the…
May 2, 2024, 01:42 |
Opinion
Sharlene Gill: My picks for special oral abstract mentions for ASCO24
Sharlene Gill shared on X: "Here we go - less than 5 weeks to ASCO24.…
Apr 26, 2024, 17:42 |
Insight
New Paper Alert! The Role of MicroRNAs in Hepatocellular Carcinoma: Understanding Tumor Microenvironment and Drug Resistance Mechanisms
The Role of MicroRNAs in Hepatocellular Carcinoma: Understanding Tumor Microenvironment and Drug Resistance Mechanisms Authors:…
Apr 13, 2024, 14:18 |
Insight
Jonathan Cohen discusses hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society
Jonathan Cohen, Director of Clinical Research at Sharett Institute of Oncology of Hadassah Medical Center,…
Apr 12, 2024, 17:36 |
Insight
Mark Yarchoan: Multicenter P1/2 trial of a personalized neoantigen vaccine + anti-PD1 in 2L HCC presented at AACR24
Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, shared on X: "Multicenter P1/2 trial of…
Apr 10, 2024, 09:52 |
Insight
David Pinato: Immunotherapy might become a novel standard of care in intermediate-stage HCC
David Pinato, Director of Developmental Cancer Therapeutics at Imperial College London, shared on LinkedIn: "Immunotherapy…
Mar 28, 2024, 02:23 |
Drugs
Angela Lamarca: Great news for patients diagnosed with Biliary Malignancies and HCC in Spain
Angela Lamarca, Consultant in Medical Oncology at Jiménez Díaz Foundation University Hospital, shared a post…
Feb 21, 2024, 18:13 |
Insight
Erman Akkus: Tremelimumab plus durvalumab (STRIDE) in HCC-HIMALAYA update
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "Tremelimumab plus durvalumab (STRIDE)…
Jan 17, 2024, 08:54 |
Blog
Antonio D'Alessio: It is a great honor to receive my third ASCO Merit Award
Antonio D'Alessio, Clinical Research Fellow at Imperial College London, recently shared on X/Twitter: "It is…
Jan 3, 2024, 18:45 |
Insight
Ada Zhong: Nice review by Janet Wui Cheung Kung and Kelvin Kwok Chai Ng
Quoting Ada Zhong, Science Editor of Hepatoma Research at OAE Publishing Inc., on LinkedIn: ''Nice…
Nov 30, 2023, 15:58 |
Blog
Aju Mathew: Rising numbers of hepatocellular carcinoma in India
Aju Mathew, Senior Medical Advisor at Karkinos Healthcare, shared on X/Twitter: "Moderating an Indian National…
Aug 25, 2023, 18:25 |
Insight
Arndt Vogel: Immune Checkpoint Inhibitors for Child-Pugh B HCC: comprehensive summary of 22 studies with 699 patients.
Quoting Arndt Vogel on X/Twitter: "Hot off the press: Immune Checkpoint Inhibitors for CP B…
All:
24
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube